---
schema_version: "secwatch.filing_event.v1"
accession: "0001935979-22-000009"
form_type: "8-K"
ticker: "BHVN"
cik: "0001935979"
company_name: "Biohaven Ltd."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:14:14.694530+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biohaven posts Q3 net loss $68.9M; launches post-Pfizer with $257.8M cash, raises $301.9M offering

## Summary
- Net loss of $68.9M ($1.75/share) vs $54.4M loss in Q3 2021; non-GAAP adjusted loss $49.2M ($1.25/share).
- Cash at Sept 30: $50.7M; post-spin-off and $301.9M public offering, pro-forma cash ~$541M with no debt.
- Spin-off from Pfizer completed Oct 3, 2022; BHVN began trading independently with $257.8M cash.
- Closed public offering of 28.75M shares at $10.50/share, gross proceeds $301.9M (net $282.8M).
- Pipeline milestones: BHV-7000 Phase 1 complete H1 2023; troriluzole Phase 3 OCD enrollment in 2023.

## SEC filing metadata
- accession: 0001935979-22-000009
- form_type: 8-K
- ticker: BHVN
- cik: 0001935979
- company_name: Biohaven Ltd.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/0001935979-22-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/bhvn-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001935979-22-000009
- JSON: https://secwatch.observer/filing/0001935979-22-000009.json
- Plain text: https://secwatch.observer/filing/0001935979-22-000009.txt

## Key facts
- Earnings Releases
  Biohaven Ltd. reported financial results for third quarter ended September 30, 2022.
  - Period: third quarter ended September 30, 2022
  - Result: reported results
  source text: issued a press release announcing its financial results for the third quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1935979/000193597922000009/0001935979-22-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.